	US 11,679,160 B2
	Castration resistant prostate cancer
Esteban Pombo-Villar, Binningen (CH); Alexander Levitzki, Jerusalem (IL); Yael Langut, Haifa (IL); Maya Zigler, Basel (CH); Alexei Shir, Jerusalem (IL); and Eric Kitas, Aesch (CH)
Assigned to TARGIMMUNE THERAPEUTICS AG, Basel (CH)
Appl. No. 16/650,980
Filed by TARGIMMUNE THERAPEUTICS AG, Basel (CH)
PCT Filed Sep. 27, 2018, PCT No. PCT/EP2018/076293 § 371(c)(1), (2) Date Mar. 26, 2020, PCT Pub. No. WO2019/063705, PCT Pub. Date Apr. 4, 2019.
Claims priority of application No. 17193577 (EP), filed on Sep. 27, 2017; and application No. 17201728 (EP), filed on Nov. 14, 2017.
Prior Publication US 2020/0230248 A1, Jul. 23, 2020
Int. Cl. A61K 47/54 (2017.01); A61K 47/65 (2017.01); A61K 47/60 (2017.01); A61K 47/59 (2017.01); C07K 7/02 (2006.01); C07K 7/06 (2006.01)

CPC A61K 47/549 (2017.08) [A61K 47/59 (2017.08); A61K 47/60 (2017.08); A61K 47/65 (2017.08); C07K 7/02 (2013.01); C07K 7/06 (2013.01)]

20 Claims

1. A method of treating castration resistant prostate cancer (CRPC) comprising administering to a patient in need thereof, an effective amount of a polyplex comprising a double stranded RNA (dsRNA) and a polymeric conjugate,

wherein said polymeric conjugate consists of a linear polyethyleneimine (LPEI), one or more polyethylene glycol (PEG) moieties, one or more linkers and one or more targeting moieties, wherein said LPEI is covalently bound to one or more PEG moieties and each of said one or more PEG moieties is conjugated via one of said one or more linkers to one of said one or more targeting moieties,

wherein each of said one or more targeting moieties is capable of binding to a cancer antigen, and wherein said cancer antigen is prostate surface membrane antigen (PSMA).